雷蒂特雷塞德
医学
卡培他滨
伊立替康
奥沙利铂
肿瘤科
结直肠癌
放射治疗
内科学
化疗
临床试验
辅助治疗
贝伐单抗
癌症
作者
Antonino De Paoli,R. Innocente,Angela Buonadonna,Giovanni Boz,Roberto Sigon,Vincenzo Canzonieri,S. Frustaci
出处
期刊:Tumori Journal
[SAGE Publishing]
日期:2004-07-01
卷期号:90 (4): 373-378
被引量:12
标识
DOI:10.1177/030089160409000402
摘要
During the past two decades, significant advances have been made in the management of patients with rectal cancer. A number of clinical studies have demonstrated the efficacy of preoperative chemoradiation therapy with 5-fluorouracil (5-FU)-based regimens in decreasing local recurrences and improving survival and the likelihood of sphincter preservation. Although 5-FU has been the standard drug used in combination with radiation therapy for many years, new effective drugs including capecitabine, raltitrexed, irinotecan and oxaliplatin have been recently investigated in combination with radiation therapy in the preoperative setting. In addition, novel targeted biological agents including epidermal growth factor receptor inhibitors and vascular endothelial growth factor inhibitors have been shown to enhance the antitumor effect of both radiation and chemotherapy and are currently being explored in initial clinical trials. In the present review we summarize the results of adjuvant therapy. In addition, we will discuss the recently reported phase I-II trials with new drug plus radiation combinations in the preoperative treatment of patients with rectal cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI